Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government.
In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology.
Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.
Company Details
- Employees
- 13
- Founded
- -
- Address
- 분당구 판교로 253, 이노밸리c동 801호,korea, Republic Of
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- http://www.rznomics.com
- Keywords
- 성남시.
- HQ
- 성남시, 경기도
Rznomics Inc. Questions
Rznomics Inc.'s website is http://www.rznomics.com
Rznomics Inc.'s LinkedIn profile is https://kr.linkedin.com/company/rznomics
Rznomics Inc. has
13 employees.
View email and phone details for 13
employees at Rznomics Inc..
Rznomics Inc.'s industry is
Research Services
Rznomics Inc.'s top competitors are
Proqr Therapeutics,
Creyon Bio,
Vertex Pharmaceuticals,
Confo Therapeutics,
Mina Therapeutics,
Nuvation Bio,
Novo Holdings,
Eli Lilly And Company,
Siteone Therapeutics, Inc.,
Akouos.
Rznomics Inc.'s categories are Research Services
Rznomics Inc.'s founding year is 2017
